Abstract
Tumor necrosis factor (TNF)-α has a key role in the development of coronary artery aneurysms in acute KD. Blockade of the TNF-α inflammatory cascade is thus a logical therapeutic aim. Infliximab, a chimeric monoclonal antibody that specifically binds TNF-α, and etanercept, a TNF-α receptor blocker, have both been used as rescue therapy for treatment-resistant KD. A prospective trial of intensification of primary therapy with infliximab in acute KD demonstrated that infliximab was safe and reduced inflammation, days of fever, and left anterior descending coronary artery diameter more rapidly than IVIG alone. A trial of etanercept as adjunctive therapy in acute KD is currently in progress.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Furukawa S, Matsubara T, Jujoh K, Yone K, Sugawara T, Sasai K, et al. Peripheral blood monocyte/macrophages and serum tumor necrosis factor in Kawasaki disease. Clin Immunol Immunopathol. 1988;48(2):247–51. http://dx.doi.org/10.1016/0090-1229(88)90088-8 PMID:3390972.
Matsubara T. Serum gamma interferon levels in relation to tumor necrosis factor and interleukin 2 receptor in patients with Kawasaki disease involving coronary-artery lesions. Arerugi. 1990;39(2 Pt 1):118–23. PMID:2112909.
Burns JC, Capparelli EV, Brown JA, Newburger JW. Glode MP; US/Canadian Kawasaki Syndrome Study Group. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. Pediatr Infect Dis J. 1998;17(12):1144–8. http://dx.doi.org/10.1097/00006454-199812000-00009 PMID:9877364.
Tremoulet AH, Best BM, Song S, Wang S, Corinaldesi E, Eichenfield JR, et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr. 2008;153(1):117–21. http://dx.doi.org/10.1016/j.jpeds.2007.12.021 PMID:18571548.
Oharaseki T, Yokouchi Y, Yamada H, Mamada H, Muto S, Sadamoto K, et al. The role of TNF-alpha in a murine model of Kawasaki disease arteritis induced with a Candida albicans cell wall polysaccharide. Mod Rheumatol. 2014;24(1):120–8. http://dx.doi.org/10.3109/14397595.2013.854061.
Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS. Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol. 2004;31(4):808–10. PMID:15088313.
Burns JC, Mason WH, Hauger SB, Janai H, Bastian JF, Wohrley JD, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr. 2005;146(5):662–7. http://dx.doi.org/10.1016/j.jpeds.2004.12.022 PMID:15870671.
Saji T, Kemmotsu Y. Infliximab for Kawasaki syndrome. J Pediatr. 2006;149(3):426. http://dx.doi.org/10.1016/j.jpeds.2005.07.039 PMID:16939768.
Son MB, Gauvreau K, Burns JC, Corinaldesi E, Tremoulet AH, Watson VE, et al. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. J Pediatr. 2011;158(4):644–9 e1. http://dx.doi.org/10.1016/j.jpeds.2010.10.012.
Son MB, Gauvreau K, Ma L, Baker AL, Sundel RP, Fulton DR, et al. Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006. Pediatrics. 2009;124(1):1–8. http://dx.doi.org/10.1542/peds.2008-0730 PMID:19564276.
Mori M, Imagawa T, Hara R, Kikuchi M, Hara T, Nozawa T, et al. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series. J Rheumatol. 2012;39(4):864–7. http://dx.doi.org/10.3899/jrheum.110877 PMID:22337241.
Jimenez-Fernandez SG, Tremoulet AH. Infliximab treatment of pancreatitis complicating acute Kawasaki disease. Pediatr Infect Dis J. 2012;31(10):1087–9. PMID:22653489.
Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2008;153(6):833–8. http://dx.doi.org/10.1016/j.jpeds.2008.06.011 PMID:18672254.
Burns JC, Song Y, Bujold M, Shimizu C, Kanegaye JT, Tremoulet AH, et al. Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin. Clin Exp Immunol. 2013;174(3):337–44. http://dx.doi.org/10.1111/cei.12182 PMID:23901839.
Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, et al. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet. 2014;383(9930):1731–8. http://dx.doi.org/10.1016/S0140-6736(13)62298-9 PMID:24572997.
Ohashi R, Fukazawa R, Watanabe M, Tajima H, Nagi-Miura N, Ohno N, et al. Etanercept suppresses arteritis in a murine model of kawasaki disease: a comparative study involving different biological agents. Int J Vasc Med. 2013;2013:543141. http://dx.doi.org/10.1155/2013/543141.
Peyre M, Laroche C, Etchecopar C, Brosset P. The role of immunosuppressive agents in Kawasaki disease: a discussion of two cases. Arch Pediatr. 2013;20(7):748–53. http://dx.doi.org/10.1016/j.arcped.2013.04.002 PMID:23693156.
de Magalhaes CM, Alves NR, de Melo AV, Junior CA, Nomicronbrega YK, Gandolfi L, et al. Catastrophic Kawasaki disease unresponsive to IVIG in a 3-month-old infant: a diagnostic and therapeutic challenge. Pediatr Rheumatol Online J. 2012;10(1):28. http://dx.doi.org/10.1186/1546-0096-10-28 PMID:22929725.
Choueiter NF, Olson AK, Shen DD, Portman MA. Prospective open-label trial of etanercept as adjunctive therapy for kawasaki disease. J Pediatr. 2010;157(6):960–6 e1. http://dx.doi.org/10.1016/j.jpeds.2010.06.014.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Japan
About this chapter
Cite this chapter
Tremoulet, A.H. (2017). Tumor Necrosis Factor-α Blockade for Treatment of Acute Kawasaki Disease. In: Saji, B., Newburger, J., Burns, J., Takahashi, M. (eds) Kawasaki Disease. Springer, Tokyo. https://doi.org/10.1007/978-4-431-56039-5_17
Download citation
DOI: https://doi.org/10.1007/978-4-431-56039-5_17
Published:
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-56037-1
Online ISBN: 978-4-431-56039-5
eBook Packages: MedicineMedicine (R0)